Tuberculosis vaccines in the era of Covid-19 – what is taking us so long?

Hazel M. Dockrell; Helen McShane

EBioMedicine (May 2022)

Tuberculosis vaccines in the era of Covid-19 – what is taking us so long?

Hazel M. Dockrell,
Helen McShane

Affiliations

Hazel M. Dockrell: Department of Infection Biology, London School of Hygiene & Tropical Medicine, Keppel Street, London WCE 7HT, UK; Corresponding author: Prof H.M. Dockrell, Department of Infection Biology, London School of Hygiene & Tropical Medicine, Keppel Street, London WCE 7HT, UK. Phone: +447595090549.
Helen McShane: The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK

Journal volume & issue: Vol. 79
p. 103993

Abstract

Read online

Summary: The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines, although there much active research and a vaccine development pipeline, with vaccines designed to prevent infection, prevent disease, or accelerate TB treatment. These vaccines are of different types, and designed to replace BCG, or to boost immunity following BCG vaccination. This viewpoint discusses why, when it has been possible to develop new vaccines for SARS-CoV-2 so quickly, it is taking so long to develop new tuberculosis vaccines.

Published in EBioMedicine

ISSN: 2352-3964 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Medicine (General)
Website: http://www.journals.elsevier.com/ebiomedicine/

About the journal

Abstract

Keywords